Adverse Events as a Potential Clinical Marker of Antitumor Efficacy in Ovarian Cancer Patients Treated With Poly ADP-Ribose Polymerase Inhibitor

BACKGROUND: PARP inhibitor (PARPi) is an important progress in ovarian cancer treatment. The available evidence suggests that BRCA mutation and homologous recombination deficiency (HRD) are effective biological markers for PARPi. Here we investigated the relationship between adverse events (AEs) and...

Descripción completa

Detalles Bibliográficos
Autores principales: Ni, Jing, Cheng, Xianzhong, Zhou, Rui, Zhao, Qian, Xu, Xia, Guo, Wenwen, Gu, Hongyuan, Chen, Chen, Chen, Xiaoxiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450569/
https://www.ncbi.nlm.nih.gov/pubmed/34552876
http://dx.doi.org/10.3389/fonc.2021.724620

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8450569/
https://www.ncbi.nlm.nih.gov/pubmed/34552876
http://dx.doi.org/10.3389/fonc.2021.724620

Ejemplares similares